3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
4
Waldenstrom Macroglobulinemia
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Multiple Myeloma
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphoma
1
Intraocular Lymphoma
1
Cardiovascular Diseases
1
Interventions
Dexamethasone
16
daratumumab
14
Bortezomib
11
Lenalidomide
9
pomalidomide
7
Calcium Dobesilate
6
isatuximab
4
belantamab mafodotin
4
Cyclophosphamide
4
carfilzomib
3
Melphalan
3
tocilizumab
2
iberdomide
2
dexamethasone acetate
2
dexamethasone 21-phosphate
2
auricularum
2
Specimen Handling
2
Maintenance
2
Injections
2
Immunotherapy, Adoptive
2
Exercise Therapy
2
Drug Therapy
2
CT103A chimeric antigen receptor
2
Biopsy
2
zanubrutinib
1
trametinib
1
talquetamab
1
selinexor
1
pembrolizumab
1
ixazomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Multiple Myeloma
×
zanubrutinib
×
Clear all
NCT07474961
2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4
Not yet recruiting
400 enrolled